Trials / Completed
CompletedNCT00756067
Evaluation of Pneumococcal Vaccine Formulations in Elderly
A Study to Evaluate GSK Biologicals' Candidate Formulations of Pneumococcal Vaccines (GSK2189241A) in Elderly Subjects.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 168 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 65 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this observer-blind study is to evaluate the safety, reactogenicity and immunogenicity of pneumococcal vaccines in elderly. Subjects will be vaccinated twice with an interval of two months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Pneumococcal vaccine GSK2189241A | Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2. |
| BIOLOGICAL | Pneumo 23™ | One dose of 0.5 ml will be administered intramuscularly at Month 0, and a placebo dose to keep the blinding at Month 2. |
Timeline
- Start date
- 2008-09-19
- Primary completion
- 2009-05-28
- Completion
- 2009-05-28
- First posted
- 2008-09-19
- Last updated
- 2017-05-10
Locations
3 sites across 1 country: Sweden
Source: ClinicalTrials.gov record NCT00756067. Inclusion in this directory is not an endorsement.